dc.contributor.author | Li, Xiangyu | |
dc.contributor.author | Yang, Hong | |
dc.contributor.author | Jin, Han | |
dc.contributor.author | Türkez, Hasan | |
dc.contributor.author | Öztürk, Gürkan | |
dc.contributor.author | Doğanay, Hamdi Levent | |
dc.contributor.author | Zhang, Cheng | |
dc.contributor.author | Nielsen, Jens | |
dc.contributor.author | Uhlen, Mathias | |
dc.contributor.author | Boren, Jan | |
dc.contributor.author | Mardinoğlu, Adil | |
dc.date.accessioned | 2023-09-11T07:30:09Z | |
dc.date.available | 2023-09-11T07:30:09Z | |
dc.date.issued | 2023 | en_US |
dc.identifier.citation | Li, X., Yang, H., Jin, H., Türkez, H., Öztürk, G., Doğanay, H. L. ... Mardinoğlu, A. (2023). The acute effect of different NAD plus precursors included in the combined metabolic activators. Free Radical Biology and Medicine, 205, 77-89. https://dx.doi.org/10.1016/j.freeradbiomed.2023.05.032 | en_US |
dc.identifier.issn | 0891-5849 | |
dc.identifier.issn | 1873-4596 | |
dc.identifier.uri | https://dx.doi.org/10.1016/j.freeradbiomed.2023.05.032 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12511/11401 | |
dc.description.abstract | NAD+ and glutathione precursors are currently used as metabolic modulators for improving the metabolic conditions associated with various human diseases, including non-alcoholic fatty liver disease, neurodegenerative diseases, mitochondrial myopathy, and age-induced diabetes. Here, we performed a one-day double blinded, placebo-controlled human clinical study to assess the safety and acute effects of six different Combined Metabolic Activators (CMAs) with 1 g of different NAD+ precursors based on global metabolomics analysis. Our integrative analysis showed that the NAD+ salvage pathway is the main source for boosting the NAD+ levels with the administration of CMAs without NAD+ precursors. We observed that incorporation of nicotinamide (Nam) in the CMAs can boost the NAD+ products, followed by niacin (NA), nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), but not flush free niacin (FFN). In addition, the NA administration led to a flushing reaction, accompanied by decreased phospholipids and increased bilirubin and bilirubin derivatives, which could be potentially risky. In conclusion, this study provided a plasma metabolomic landscape of different CMA formulations, and proposed that CMAs with Nam, NMN as well as NR can be administered for boosting NAD+ levels to improve altered metabolic conditions. | en_US |
dc.description.sponsorship | PoLiMeR Innovative Training Network (Marie Sklodowska-Curie Grant) - European Union's Horizon 2020 research and innovation program ; Knut & Alice Wallenberg Foundation ; Uppsala Multidisciplinary Center for Advanced Computational Science (UPPMAX) ; ScandiBio Therapeutics | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Elsevier Science Inc | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | NAD+ Precursors | en_US |
dc.subject | Serine | en_US |
dc.subject | Cysteine | en_US |
dc.subject | Carnitine | en_US |
dc.subject | Metabolomics | en_US |
dc.subject | Systems Medicine | en_US |
dc.title | The acute effect of different NAD plus precursors included in the combined metabolic activators | en_US |
dc.title.alternative | The acute effect of different NAD+ precursors included in the combined metabolic activators | en_US |
dc.type | article | en_US |
dc.relation.ispartof | Free Radical Biology and Medicine | en_US |
dc.department | İstanbul Medipol Üniversitesi, Rektörlük, Sağlık Bilim ve Teknolojileri Araştırma Enstitüsü | en_US |
dc.authorid | 0000-0003-0352-1947 | en_US |
dc.identifier.volume | 205 | en_US |
dc.identifier.startpage | 77 | en_US |
dc.identifier.endpage | 89 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.doi | 10.1016/j.freeradbiomed.2023.05.032 | en_US |
dc.institutionauthor | Öztürk, Gürkan | |
dc.identifier.wosquality | Q1 | en_US |
dc.identifier.wos | 001053802900001 | en_US |
dc.identifier.scopus | 2-s2.0-85161276991 | en_US |
dc.identifier.pmid | 37271226 | en_US |
dc.identifier.scopusquality | Q1 | en_US |